How much funding has Engrail Therapeutics raised?

Engrail Therapeutics has raised $221.0M in total funding, most recently a Series B round.

When was Engrail Therapeutics founded?

Engrail Therapeutics was founded in 2019.

Where is Engrail Therapeutics headquartered?

Engrail Therapeutics is headquartered in San Diego, California, United States.

What industry is Engrail Therapeutics in?

Engrail Therapeutics operates in Biotech, Drug Discovery, Healthcare, Therapeutics.

How many employees does Engrail Therapeutics have?

Engrail Therapeutics has 11-50 employees.

Engrail Therapeutics

Q: Who are Engrail Therapeutics's investors?

Engrail Therapeutics's investors include F-Prime Capital, Forbion Capital Partners, Shiv Chaudhary.

Precision Neuroscience. Transformational Therapies.

San Diego, United States · Founded 2019 · $221.0M raised

Headquarters: San Diego, California
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: engrail.com
Total Funding: $221.0M
Last Round: $157.0M Series BMar 2024
Rounds: 3

About

Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted neuroscience therapies for neuropsychiatric and neurodevelopmental diseases. Its pipeline includes ENX-102 (GABA-A PAM for generalized anxiety disorder) and ENX-104 (for major depressive disorder with anhedonia), both in Phase 2 trials. The company raised a $157M Series B in 2024 to advance its programs.

Summary

Engrail Therapeutics is a Biotech company based in San Diego, United States, founded in 2019. It has raised $221.0M in total across 3 rounds, most recently a $157.0M Series B round in Mar 2024. Investors include F-Prime Capital, Forbion Capital Partners and Shiv Chaudhary.

LinkedIn X (Twitter)